GPCR vs ARWR vs HALO vs AMGN vs ALNY

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 9. 9% for Amgen Inc. (AMGN). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Structure Therapeutics Inc. (GPCR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amgen Inc.

(AMGN) is the cheapest at 23. 1x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus Amgen Inc. 's 5. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to +17. 4% for Arrowhead Pharmaceuticals, Inc. (ARWR). Over 10 years, the gap is even starker: ARWR returned +1162% versus GPCR's +50. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus Arrowhead Pharmaceuticals, Inc. 's 1. 74β — meaning ARWR is approximately 239% more volatile than HALO relative to the S&P 500. On balance sheet safety, Structure Therapeutics Inc. (GPCR) carries a lower debt/equity ratio of 0% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 9. 9% for Amgen Inc. (AMGN). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -0. 2% for Arrowhead Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for GPCR. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus Amgen Inc. 's 5. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 0x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 32. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GPCR: 193. 1% to $114. 75.

In this comparison, AMGN (2.

9% yield) pays a dividend. GPCR, ARWR, HALO, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 61), 2. 9% yield, +158. 1% 10Y return). Arrowhead Pharmaceuticals, Inc. (ARWR) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMGN: +158. 1%, ARWR: +1162%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GPCR is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; HALO is a small-cap high-growth stock; AMGN is a mid-cap quality compounder stock; ALNY is a mid-cap high-growth stock. AMGN pays a dividend while GPCR, ARWR, HALO, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.